论文信息 - Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort - 字舞流文

Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort

U. Mellqvist | S. Trudel | E. Leip | M. Hansson | D. White | C. Min | A. Kudla | A. Alegre | T. Ikeda | S. Grosicki | K. Sunami | Youngil Koh | Jacob Crafoord | Łukasz Pruchniewski | G. Finn | Y. Koh